Tim Akhurst - Concepedia

Author

Tim Akhurst

Also Known As

T Akhurst, T. Akhurst, T. J. Akhurst, TIM Akhurst, Tim Akhurst, Tim J Akhurst, Tim J. Akhurst, on behalf of the TheraP Investigators and the ANZUP Cancer Trials Group

112

Publications

6.4K

Citations

H-Index

Concepts

All Affiliations

Peter MacCallum Cancer Centre The University of Melbourne Memorial Sloan Kettering Cancer Center Monash University Austin Health

About

Tim Akhurst is an author at Peter MacCallum Cancer Centre specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	24	1.9K
2	Health Sciences	10	10	740
3	Engineering	3	3	360
4	Natural Sciences	1	1	60
5	Biochemistry	1	1	60

Tim Akhurst

Publications

6.1K

Citations

H-Index

Page 1

	Year	Citations
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study Michael S. Hofman, John Violet, Rodney J. Hicks, The Lancet Oncology	2018	1.1K
Dosimetry of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes John Violet, Price Jackson, Justin Ferdinandus, Journal of Nuclear Medicine	2018	454
Lessons Learned From 500 Cases of Lymphatic Mapping for Breast Cancer Arnold Hill, Katherine N. Tran, Tim Akhurst, Annals of Surgery	1999	363
Whole Body <sup>18</sup>FDG-PET and the Response of Esophageal Cancer to Induction Therapy: Results of a Prospective Trial Robert J. Downey, Tim Akhurst, David H. Ilson, Journal of Clinical Oncology	2003	320
Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology Thomas Beyer, Gerald Antoch, Todd M. Blodgett, European Journal of Nuclear Medicine and Molecular Imaging Computed TomographyEngineeringRespiratory MotionMedical ImagingOncologic Imaging	2003	298
Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus Gregory J. Riely, Mark G. Kris, Binsheng Zhao, Clinical Cancer Research	2007	284
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup>Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer John Violet, Shahneen Sandhu, Amir Iravani, Journal of Nuclear Medicine	2019	269
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial James P Buteau, Andrew Martin, Louise Emmett, The Lancet Oncology Biomarker (Medicine)Prognostic BiomarkersUrologyOncologyBiomarker Analysis	2022	239
68Ga-DOTATATE and 18F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity Chian A. Chang, David A. Pattison, Richard W. Tothill, Cancer Imaging	2016	186
Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy Sue Ping Thang, John Violet, Shahneen Sandhu, European Urology Oncology UrologyPoor OutcomesGenitourinary CancerMedicineExpression Deemed Ineligible	2018	178

Page 1